Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) has completed formal supplier qualification processes for five in-vitro diagnostics manufacturers. The company said the approvals allow it to supply products across several diagnostic product lines, although they do not guarantee that contracts will be awarded.
#Qualification covered five major diagnostics companies
Microbix said each of the five manufacturers is considered to be among the ten largest companies of its type by revenues. The businesses were not identified, with the company citing confidentiality provisions.
The qualification work included supplier audits and quality reviews. In multiple cases, Microbix underwent multi-day on-site assessments covering manufacturing, quality control, quality assurance, ISO compliance and other business systems.
#Products covered by the approvals
The completed qualification processes allow Microbix to supply antigens, QAPs™, ONBOARDx™ kits, QUANTDx® reference materials and reagents to the qualified Dx Test-Makers.
Microbix describes its antigens as materials used in tests assessing prior exposure to, immunity from or an acute reaction to infectious pathogens. Its QAPs are patient-sample mimetics used as test controls, while ONBOARDx kits are customised QAP packages intended to support the qualification of testing sites and the initial and periodic training of technicians.
QUANTDx reference materials are characterised and quantified materials used in assay development and as quality-control release standards for assay manufacturing.
#Qualification does not confirm new contracts
Microbix stated that supplier approval does not ensure it will receive material contracts from any of the five manufacturers. The company said the qualification should make potential opportunities more available when new projects arise, but it did not announce awarded contracts in connection with the qualification.
Microbix also said that recognition as a fully vetted supplier may help it pursue business with smaller diagnostics companies that do not have the resources to conduct similarly detailed qualification exercises. This was presented as a potential opportunity rather than confirmed business.
#Management comments and company context
Cameron Groome, Microbix’s CEO and President, said the company aims to secure and disclose new business with one or more of the qualified manufacturers. His comments did not provide a timetable or guarantee that such business will be obtained.
Microbix reported 120 employees and revenues of C$ 18.6 million in its latest fiscal year (2025). The Mississauga, Ontario-based company develops biological products for the diagnostics industry, including antigens, QAPs and QUANTDx reference materials. Its QAPs are available in over 30 countries, according to the company.
#Risks and forward-looking statements
Microbix said forward-looking information in its announcement is inherently uncertain and that actual future events, conditions and results may differ materially from management’s estimates, beliefs, intentions and expectations.
The risks identified by the company include financial results and stability, regulatory compliance and approvals, access to and sales in foreign jurisdictions, production costs, quality, quantity and delivery timing, currency exchange rates, maintaining adequate working capital and raising new capital on acceptable terms or at all.
#Key Takeaways
- Microbix completed formal supplier qualification processes for five in-vitro diagnostics manufacturers.
- The five companies are each considered to be among the ten largest such businesses by revenues, but their names were not disclosed.
- The qualification covers antigens, QAPs™, ONBOARDx™ kits, QUANTDx® reference materials and reagents.
- Microbix said the qualification does not guarantee material contracts or confirm new business.
- The company said the status may create potential opportunities with the qualified manufacturers and smaller diagnostics companies.
Original source: Read original article